Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.

Lake Park Dental Celebrates Gorgeous Grandma Day With a Toast to Milwaukee Smiles

This Gorgeous Grandma Day, Lake Park Dental in Milwaukee spotlights how modern, metal-free implants help women 55 and up smile with confidence again. The post Lake Park Dental Celebrates Gorgeous Grandma Day With a Toast to Milwaukee Smiles first appeared on

Closing of Previously Announced Restructuring Transaction in Connection with CCAA Proceedings

MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 by the Royal Bank of Canada (the “ Applicant ”) in its capacity as a secured creditor (the “ CCAA Proceedings ”) and the Court-approved restructuring transaction announced on July 3, 2026, Polar Valley Investments Limited (“ Polar ”) has successfully closed the acquisition of all of the equity interests in three affiliates of the Company, namely Solutions Staffing Inc. (“ SSI ”), Canadian Health Care Agency Ltd. (“ CHCA ”) and Premier Soin Nordik Inc. / Premier Health Nordik Inc. (“ Nordik Québec ”) (the “ Transaction ”).

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten...

QUINT Reviews 2026: Why Q.SCALP and Q.FACE Are Winning Over Buyers Seeking a Smarter Monthly Routine

As consumers look beyond demanding daily hair and skincare regimens, this QUINT review explores why Q.SCALP and Q.FACE are attracting attention, how the brand positions its once-monthly exosome-serum systems, and what buyers should confirm about pricing, subscriptions, FDA status, and guarantee terms before ordering.

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Crescent from the offering

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a...

Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis

HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9...

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged...

United Kingdom Digital Health Market Size to Reach USD 43.98 Billion by 2031, Driven by NHS Digitalization

BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600

NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS) in the S&P MidCap 400, and Karman Holdings Inc. (NYSE: KRMN) will replace BrightSpring Health Services in the S&P SmallCap...